Cephalon exercises option to acquire Ception for $250 million

Cephalon offered $250 million to purchase Ception Therapeutics, exercising an exclusive option to acquire the company as part of a $100 million deal previously signed. The move comes after Cinquil, Ception's drug candidate for eosinophilic asthma, yielded positive results in a clinical trial.

View Full Article in:

American City Business Journals · Wall Street Journal, The

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Sr. Regulatory Specialist, Biotech Center of Expertise
BASF, The Chemical Co.
San Diego, CA
Food Lawyer
Wayzata, MN
Director of Clinical Research
Regenesis Biomedical, Inc.
Scottsdale, AZ
Meridian Health Plan
Detroit, MI
Assistant Vice President - Dental Director
Bridgewater, NJ